With the increasing number of individuals with diabetes and obesity, nonalcoholic fatty liver
disease (NAFLD) is becoming increasingly prevalent, affecting one-quarter of adults …

Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …

Non-alcoholic fatty liver disease (NAFLD) is a major public health problem afflicting
approximately one billion individuals worldwide. Liver biopsy is considered the gold …

Key issues in patients with nonalcoholic fatty liver disease (NAFLD) are the differentiation of
nonalcoholic steatohepatitis (NASH) from simple steatosis and staging of liver fibrosis, as …

Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of
chronic liver disease in the United States affecting approximately 80–100 million Americans …

The correct identification of patients at increased risk of non-alcoholic steatohepatitis
(NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver …

Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of liver-related
morbidity and mortality worldwide, afflicting approximately a billion individuals. NAFLD is a …

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of histopathologic features,
ranging from isolated hepatic steatosis, to steatohepatitis with evidence of hepatocellular …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver pathologies characterized by
hepatic steatosis with a history of little to no alcohol consumption or secondary causes of …

Non-Alcoholic Fatty Liver Disease (NAFLD) is currently the most common cause of chronic
liver disease worldwide, and its prevalence is increasing globally. NAFLD is a multifaceted …